Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A-SUQAR is a chewable dietary supplement developed by Bioxytran, Inc., designed to support healthy post-meal blood sugar levels. The product's active ingredient is a proprietary formulation of partially hydrolyzed guar gum (PHGG), which is based on Bioxytran's carbohydrate-based galectin platform technology. A-SUQAR functions as a nutraceutical that slows the digestion of carbohydrates in the gastrointestinal tract, thereby preventing sharp spikes in blood glucose after meals. It is intended to be taken as an oral chewable tablet before eating. Bioxytran has entered into a distribution agreement with Khoury Medical LTD for the commercialization of the product, with initial commercial shipments anticipated to begin in 2026.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on A-SUQAR.